# Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma

> **NCT00058279** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Intraocular Melanoma
- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** ipilimumab

## Key facts

- **NCT ID:** NCT00058279
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** —
- **Final completion:** 2006-08
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00058279

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00058279, "Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00058279. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*